Hersentumoren

Recently closed projects / recent gesloten projecten / projets récemment fermés / kürzlich geschlossene Projekte

Phase 3 study of Enzastaurin versus Lomustine in the treatment of glioblastoma multiforme. Enzastaurin is a potent selective inhibitor of PKCβ; Lomustine is a nitrosourea agent. Study group/sponsor: Eli Lilly.

Phase III study with Temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss (EORTC 26033). Temozolomide is an alkylating agent. Study group/sponsor: EORTC. Contact: Prof. P. Clement.

Phase III study with Cilengitide in patients with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter. Cilengitide is an angiogenesis inhibitor. Study group/sponsor: Merck. Contact: Prof. P. Clement.

Phase III study of radiotherapy versus Temozolomide versus radiotherapy with concomitant and adjuvant Temzolomide in newly diagnosed anaplastic oligodendroglioma or anaplastic mixed glioma with chromosomal co-deletions of 1p and 19q (EORTC 26081)). Study group/sponsor: EORTC. Contact: Prof. P. Clement (in collaboration with Prof. J. Menten)

Ongoing projects / lopende projecten / projets actifs / laufende Projekte

Protocol EORTC 26053: phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma (EORTC 26053). Temozolomide is an alkylating agent. Study group/sponsor: EORTC. Contact Prof. P. Clement. For further information, please visit the website www.cancertrials.be.

Protocol EORTC 26091: randomized trial assessing the significance of bevacizumab in recurrent grade II and grade III gliomas: TAVAREC. Study group/sponsor: EORTC. Contact: Prof. P. Clement. For further information, please visit the website www.cancertrials.be.

Protocol EORTC 26101: phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. Study group/sponsor: EORTC Brain Tumour Group. Contact: Prof. Dr. P. Clement. For further information, please visit the website www.cancertrials.be.

Protocol GO28909 (Daf study): Phase Ib, open-label study of the safety and pharmacology of MEHD7945A in combination with either cisplatin or 5-FU or paclitaxel and carboplatin in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Study group/sponsor: Roche. Contact: Prof. Dr. P. Clement. For further information, please visit the website www.cancertrials.be.

Planned projects / geplande projecten / projets en développement / geplante Projekte

Protocol CBKM120E2102: Phase Ib/II open-label study of buparlisib plus carboplatin or CCNU in patients with recurrent glioblastoma multiforme (GBM). Study group/sponsor: Novartis. Contact: Prof. Dr. P. Clement/Prof. Dr. P. Schöffski. For further information, please visit the website www.cancertrials.be.

Protocol CBGJ398X2201: A phase II, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable glioblastoma. Study group/sponsor: Novartis. Contact: Prof. Dr. P. Clement. For further information, please visit the website www.cancertrials.be.

Protocol CA209-143: A study to establish the safety, tolerability and efficacy of nivolumab and nivolumab in combination with ipilimumab versus standard of care treatment (bevacizumab) in patients diagnosed with recurrent glioblastoma. Study group/sponsor: Bristol-Myers Squibb. Contact: Prof. Dr. P. Clement. For further information, please visit the website www.cancertrials.be.